GLP-1 Drugs and Menstrual Changes

A pharmacovigilance study published in July 2026 in Obstetrics and Gynecology found that semaglutide and tirzepatide are associated with disproportionate reporting of several menstrual adverse events in reproductive-aged females. ^[1] The findings add a new dimension to the risk conversation that clinicians have with patients on these drugs.

What the study looked at

Researchers Connor Frey and Mahyar Etminan used FDA Adverse Event Reporting System (FAERS) data through March 2026. ^[1] They restricted the analysis to female patients aged 12 to 55 years and examined five menstrual outcomes: heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea (infrequent periods), and anovulatory cycles. They applied disproportionality and Bayesian analyses to three GLP-1 class drugs: semaglutide, tirzepatide, and liraglutide.

Disproportionality analysis is the standard method in pharmacovigilance. It does not establish causation. Instead, it identifies whether a drug is reported with a particular adverse event more often than would be expected by chance given the full FAERS database. A positive signal means the pairing appears at higher-than-background frequency; it does not confirm the drug caused the event.

What the signals showed

Semaglutide showed a positive signal across all five menstrual outcomes examined. ^[1] Tirzepatide generated signals for intermenstrual bleeding and menstrual clots. Liraglutide, an older GLP-1 receptor agonist now less commonly prescribed for obesity, produced no significant signals for any of the five outcomes.

The authors noted that the signal differences between drugs may reflect several factors: the much larger number of semaglutide users in FAERS (giving more statistical power to detect signals), genuine pharmacological differences in receptor selectivity, and the recency of tirzepatide's wider rollout. The absence of a signal for liraglutide does not necessarily mean it has no menstrual effects; it may reflect lower reporting volume.

A possible biological pathway

The authors suggest these findings point to "pleiotropic effects on menstrual physiology" from GLP-1 receptor activation. ^[1] GLP-1 receptors are expressed in several tissues outside the gut and pancreas, including the ovaries and hypothalamus, both of which are central to the hormonal regulation of the menstrual cycle.

Separate preclinical research published in Diabetes, Obesity and Metabolism in January 2026 found that the estrous cycle (the rodent analog of the human menstrual cycle) moderates how strongly GLP-1 receptor agonists suppress food intake and body weight. ^[2] GLP-1 receptor gene expression in the brain was significantly higher during the proestrus/estrus phases than during metestrus/diestrus. The authors noted possible translational implications for how the timing of GLP-1 receptor agonist administration across the menstrual cycle might affect therapeutic response in women.

A randomized controlled trial in women with polycystic ovary syndrome (PCOS) found that combined semaglutide and metformin therapy led to higher rates of menstrual cycle recovery than metformin alone after 16 weeks. ^[3] That finding, while not addressing the adverse-event signals in the FAERS study, illustrates that GLP-1 drug effects on the menstrual cycle can go in more than one direction depending on the patient's underlying hormonal context.

Existing prescribing information and the oral contraceptive warning

The current prescribing information for tirzepatide (Mounjaro) does not mention menstrual cycle disruption as an adverse effect. ^[4] It does carry a separate caution about oral contraceptive absorption: because tirzepatide delays gastric emptying, it can reduce how much of an oral contraceptive pill is absorbed. Patients are advised to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation. This guidance is about absorption mechanics, not about direct hormonal effects on the cycle.

The FAERS-based findings from Frey and Etminan suggest that label updates for both semaglutide and tirzepatide may eventually be warranted, pending replication in prospective data. FAERS signals are considered hypothesis-generating rather than confirmatory.

What this means in practice

The study's authors recommend that menstrual health be included in counseling discussions with reproductive-aged patients who are prescribed GLP-1 receptor agonists. That is consistent with standard clinical practice: any new symptom pattern in a patient starting a new medicine warrants a conversation with the prescribing clinician.

If you are a reproductive-aged patient on semaglutide or tirzepatide and you notice changes to your cycle, the appropriate step is to raise this with your prescriber. It should not be assumed that the drug is the cause, but it should not be dismissed either. Several other factors, including weight loss itself, caloric restriction, and changes in insulin sensitivity, can affect menstrual regularity independently of any direct drug effect.

Limitations of the evidence

FAERS data carry known limitations. ^[1] Reports are submitted voluntarily by patients, clinicians, and manufacturers; under-reporting is common and uneven. Information on confounding variables (body weight, underlying conditions, concurrent medications) is incomplete. Semaglutide has far more prescriptions and a longer market history than tirzepatide, which affects signal detection. The study cannot determine whether the reported menstrual events were caused by the drugs, by weight loss, by changes in insulin levels, or by some combination. Prospective cohort studies or registry data are needed to move from signal to established risk.

This is a field where the evidence is actively evolving. The 2026 FAERS analysis is the first structured pharmacovigilance study to focus specifically on menstrual outcomes in GLP-1 drug users, which itself reflects how recently these drugs became widely prescribed in younger female populations.

Editorial note

This article is based on a published pharmacovigilance study and is intended for general educational purposes only. It is not medical advice. If you take a GLP-1 receptor agonist and have concerns about menstrual changes, consult your prescribing clinician.